Neubase Therapeutics Stock Fundamentals
| NBSE Stock | USD 0.44 0.02 4.76% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
At present, NeuBase Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 40.2 M, whereas Gross Profit is forecasted to decline to (1.5 M). NeuBase | Select Account or Indicator |
NeuBase Therapeutics Company Return On Equity Analysis
NeuBase Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current NeuBase Therapeutics Return On Equity | -0.93 |
Most of NeuBase Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
NeuBase Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, NeuBase Therapeutics has a Return On Equity of -0.9346. This is 96.1% lower than that of the Biotechnology sector and 97.44% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
NeuBase Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NeuBase Therapeutics's current stock value. Our valuation model uses many indicators to compare NeuBase Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeuBase Therapeutics competition to find correlations between indicators driving NeuBase Therapeutics's intrinsic value. More Info.NeuBase Therapeutics is regarded fifth in return on equity category among related companies. It is rated below average in return on asset category among related companies . At present, NeuBase Therapeutics' Return On Equity is projected to drop based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value NeuBase Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NeuBase Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NeuBase Therapeutics' earnings, one of the primary drivers of an investment's value.NeuBase Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in return on equity category among related companies.
NeuBase Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (5.6 M) | ||||
| Shares Outstanding | 3.75 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 12.68 % | ||||
| Number Of Shares Shorted | 24.46 K | ||||
| Price To Earning | (4.17) X | ||||
| Price To Book | 0.18 X | ||||
| EBITDA | (32.49 M) | ||||
| Net Income | (33.78 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 6 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 2.45 X | ||||
| Cash Flow From Operations | (29.01 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (18.60) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 140.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.96 | ||||
| Market Capitalization | 1.65 M | ||||
| Total Asset | 32.69 M | ||||
| Retained Earnings | (102.74 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 4.14 M | ||||
| Current Liabilities | 1.6 M | ||||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 639.3 K | 671.2 K | |
| Total Revenue | 0.00 | 0.00 | |
| Cost Of Revenue | 1.1 M | 1.1 M | |
| Stock Based Compensation To Revenue | 0.00 | 0.00 | |
| Sales General And Administrative To Revenue | 0.18 | 0.17 | |
| Research And Ddevelopement To Revenue | 0.17 | 0.15 | |
| Capex To Revenue | (0.01) | (0.01) | |
| Revenue Per Share | 3.4 K | 1.9 K | |
| Ebit Per Revenue | 2.20 | 3.62 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeuBase Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeuBase Therapeutics' short interest history, or implied volatility extrapolated from NeuBase Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out NeuBase Therapeutics Piotroski F Score and NeuBase Therapeutics Altman Z Score analysis. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.